Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
30.07 USD | +2.59% | +2.28% | +3.90% |
Sales 2024 * | 601M 48.15B | Sales 2025 * | 615M 49.21B | Capitalization | 1.65B 132B |
---|---|---|---|---|---|
Net income 2024 * | 7M 560M | Net income 2025 * | -24M -1.92B | EV / Sales 2024 * | 2.74 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 2.68 x |
P/E ratio 2024 * |
-3,007
x | P/E ratio 2025 * |
-69.9
x | Employees | 652 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.88% |
Latest transcript on Supernus Pharmaceuticals, Inc.
1 day | +2.59% | ||
1 week | +2.28% | ||
Current month | -11.84% | ||
1 month | -7.42% | ||
3 months | +4.70% | ||
6 months | +32.35% | ||
Current year | +3.90% |
Managers | Title | Age | Since |
---|---|---|---|
Jack Khattar
FOU | Founder | 62 | 29/03/05 |
Timothy Dec
DFI | Director of Finance/CFO | 66 | 22/08/21 |
Frank Mottola
CTO | Chief Tech/Sci/R&D Officer | 52 | 31/12/04 |
Members of the board | Title | Age | Since |
---|---|---|---|
Georges Gemayel
BRD | Director/Board Member | 64 | 22/03/15 |
Charles Newhall
CHM | Chairman | 79 | 29/03/05 |
John Siebert
BRD | Director/Board Member | 84 | 31/12/10 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.94% | 29 M€ | -4.33% | ||
0.94% | 16 M€ | -8.49% | ||
0.38% | 27 M€ | -5.03% | - |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 30.07 | +2.59% | 330,640 |
25/04/24 | 29.31 | -3.14% | 351,464 |
24/04/24 | 30.26 | +1.04% | 201,715 |
23/04/24 | 29.95 | +0.81% | 201,175 |
22/04/24 | 29.71 | +1.05% | 352,474 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.90% | 1.65B | |
+5.31% | 70.44B | |
+10.97% | 8.94B | |
-16.83% | 4.75B | |
+43.48% | 4.5B | |
+3.20% | 3.85B | |
+18.82% | 2.38B | |
-21.36% | 2.34B | |
-29.67% | 2.2B | |
+8.38% | 1.96B |
- Stock Market
- Equities
- SUPN Stock